Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Vila Franca De Xira – page 8

673 clinical trials in Vila Franca De Xira, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Vila Franca De Xira at a glance
673
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

673 trials in Vila Franca De Xira

Open in trial search

Study of Grass Pollen Extract and Olive Pollen Extract for Patients with Hay Fever and Asthma caused by Grass and Olive Pollen Allergies

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dactylis Glomerata Pollen Extract
  • Sponsor:LETI Pharma S.L.U.

A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:Liquidia Technologies Inc.

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-142
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

A study to evaluate the safety and efficacy of ivosidenib, decitabine, and cedazuridine in adults with newly diagnosed acute myeloid leukemia who are older than 60 or cannot receive intensive chemotherapy.

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cedazuridine
  • Sponsor:Fundacion Pethema

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Olema Pharmaceuticals Inc.

Study of ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Kura Oncology Inc.

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

A study testing the safety and effectiveness of BP1.

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:BP1.4979
  • Sponsor:Bioprojet Pharma

Cardiac failure+1

Recruiting

A study of finerenone with standard treatment for children and young adults from birth to 18 years with heart failure and left ventricular systolic dysfunction

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Cardiac failure+1

Recruiting

A study of finerenone added to standard treatment in children aged 6 months to under 18 years with heart failure and reduced left heart pumping function

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Study of Trastuzumab Deruxtecan Versus Chemotherapy as Additional Treatment After Surgery for Patients with HER2-Positive Endometrial Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

A study comparing under-the-skin and into-the-vein alpha1-proteinase inhibitor treatment in patients with alpha1-antitrypsin deficiency

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:ALPHA-1-ANTITRYPSIN
  • Sponsor:Grifols Therapeutics LLC

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Vila Franca De Xira

What the registry says about research in the country

01 Oncology Research

Innovative clinical research focusing on breast cancer treatment, specifically targeting patients with node-positive, estrogen receptor-positive, HER2-negative early-stage disease. The trials aim to evaluate new endocrine therapy approaches for improving patient outcomes.

  • Early-stage breast cancer
  • Hormone receptor-positive disease
  • High-risk recurrence cases

Research explores novel therapeutic options to enhance survival rates in breast cancer patients.

02 Nephrology Studies

Comprehensive research into chronic kidney disease and related conditions, investigating innovative treatments for reducing protein excretion and improving kidney function. Multiple trials are examining novel therapeutic compounds.

  • Chronic kidney disease management
  • Focal segmental glomerulosclerosis
  • Protein excretion disorders

Studies focus on developing targeted treatments for various kidney disorders and their complications.

03 Cardiovascular-Renal Research

Advanced clinical trials investigating the intersection of cardiovascular disease and end-stage kidney disease. Research focuses on innovative treatments for patients undergoing dialysis, with particular attention to inflammatory markers.

  • Atherosclerotic cardiovascular disease
  • End-stage kidney disease
  • Dialysis-related complications

These studies aim to improve outcomes for patients with complex cardiovascular-renal conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.